

ASX Announcement

14 July 2026

OncoSil Medical to Present OSPREY Registry Results at 2026 EANM Congress

Sydney, Australia – 14 July 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that the abstract for the Company's ongoing OSPREY register has been accepted at the 2026 European Association of Nuclear Medicine (EANM'26) Congress which will take place in Vienna (Austria) on October 17-21, 2026.

The abstract is titled:

***"Initial Outcomes from the OSPREY Registry of Patients with Unresectable Locally Advanced Pancreatic Cancer Treated with EUS-Guided Phosphorus-32 Microparticles plus Gemcitabine-Based Chemotherapy in Routine Clinical Practice."*¹**

EANM'26 is Europe's leading congress for nuclear medicine, molecular imaging, and theranostics, bringing together thousands of professionals from around the world. The conference welcomed over 9,400 attendees at EANM'25.

OSPREY is a post-market, multi-centre, observational, prospective registry collecting data on patients with unresectable LAPC receiving external ultrasound (EUS)-guided implantation of 32P-microparticles (OncoSil™ device) plus gemcitabine-based chemotherapy in routine clinical practice. To date the registry has enrolled 83 patients, with data reported on 64 patients to date. *Clinicaltrials.gov identifier NCT04493632*.

Click [HERE](#) to view this announcement on Investor Hub.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703
---	--

¹ The OSPREY data to be presented is consistent with ASX announcement dated 15 May 2026

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Australia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

¹ <https://gco.iarc.fr/en>